Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 2/20 | 1.00 |
| ▸ | OAT | P04181 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18717800 | 1.00 | ABAT (1.00) | ABATOATGABRR1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL22645698 | 0.98 | ABAT (0.96) | ABATOATGABRR1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL22645697 | 0.98 | ABAT (0.96) | ABATOATGABRR1TSHRMAPK1 | |
| SCHEMBL25405315 | 0.83 | ABAT (0.71) | ABATOATGABRR1TSHRMAPK1 | |
| SCHEMBL29276851 | 0.83 | ABAT (0.71) | ABATOATGABRR1TSHRMAPK1 | |
| SCHEMBL18717795 | 0.77 | ABAT (0.62) | ABATOAT | |
| SCHEMBL22661090 | 0.75 | ABAT (0.59) | ABATTSHRHSD17B10KMT2A | |
| Hydrochloric Acid SCHEMBL25434443 | 0.70 | ABAT (0.54) | ABATOATGABRR1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL25434445 | 0.70 | ABAT (0.54) | ABATOATGABRR1TSHRMAPK1 | |
| SCHEMBL29979297 | 0.67 | ABAT (0.50) | ABATOATGABRR1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117550990-A | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2024-02-13 | — | — | CN | claimed |
| CN-117550991-A | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2024-02-13 | — | — | CN | claimed |
| CN-112770739-B | Use of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid and related compounds for the treatment of developmental disorders | 奥维德医疗公司 | 2023-12-12 | — | — | CN | claimed |
| CN-112513006-B | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2023-10-31 | — | — | CN | claimed |
| CN-112770739-A | Use of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S) -3-amino-4- (difluoromethylene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders | 奥维德医疗公司 | 2021-05-07 | — | — | CN | claimed |
| CN-112513006-A | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2021-03-16 | — | — | CN | claimed |
| CN-112261938-A | Use of (1S,3S) -3-amino-4- (difluoromethylene) cyclopentane-1-carboxylic acid and (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere 'S disease, Tourette' S syndrome, attention deficit hyperactivity disorder and addiction | 奥维德医疗公司 | 2021-01-22 | — | — | CN | claimed |
| CN-112218628-A | Use of (1S,3S) -3-amino-4- (difluoromethylene) cyclopentane-1-carboxylic acid and (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid in the treatment of ocular disorders | 奥维德医疗公司 | 2021-01-12 | — | — | CN | claimed |
| CN-117550991-B | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2026-01-16 | — | — | CN | disclosed |
| US-12331006-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | NORTHWESTERN UNIVERSITY (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4410773-A2 | PROCESS FOR THE SYNTHESIS OF (S) 3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | Northwestern University (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-3784649-B1 | PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | UNIV NORTHWESTERN (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-117550991-A | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2024-02-13 | — | — | CN | disclosed |
| CN-117550991-A | Process for the synthesis of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid | 西北大学 | 2024-02-13 | — | — | CN | disclosed |
| CN-112261938-A | Use of (1S,3S) -3-amino-4- (difluoromethylene) cyclopentane-1-carboxylic acid and (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere 'S disease, Tourette' S syndrome, attention deficit hyperactivity disorder and addiction | 奥维德医疗公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112218628-A | Use of (1S,3S) -3-amino-4- (difluoromethylene) cyclopentane-1-carboxylic acid and (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid in the treatment of ocular disorders | 奥维德医疗公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112218628-A | Use of (1S,3S) -3-amino-4- (difluoromethylene) cyclopentane-1-carboxylic acid and (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid in the treatment of ocular disorders | 奥维德医疗公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112218628-A | Use of (1S,3S) -3-amino-4- (difluoromethylene) cyclopentane-1-carboxylic acid and (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid in the treatment of ocular disorders | 奥维德医疗公司 | 2021-01-12 | — | — | CN | disclosed |
| US-10836708-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | NORTHWESTERN UNIVERSITY (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836708-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | NORTHWESTERN UNIVERSITY (US) | 2020-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836708-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | SULT1E1, QPCT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABAT 108/4885OAT 701/4885GABRR1 1179/4885 |
| US-12331006-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | SULT1E1, QPCT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABAT 108/4885OAT 701/4885GABRR1 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.